We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

19 hedge funds and large institutions have $734K invested in Cellectar Biosciences in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.59% less ownership

Funds ownership: 11.3% → 5.71% (-5.6%)

41% less funds holding

Funds holding: 32 → 19 (-13)

68% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 19

77% less capital inflows, than outflows

Capital inflows: $191K | Capital outflows: $833K

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

Holders
19
Holders Change
-13
Holders Change %
-40.63%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
9
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HRT Financial
HRT Financial
New York
+$96.6K
2
Riverview Capital Advisers
Riverview Capital Advisers
Massachusetts
+$91.9K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$1.71K
4
Raymond James Financial
Raymond James Financial
Florida
+$1.16K
5
Group One Trading
Group One Trading
Illinois
+$79

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$237K
2
Squarepoint
Squarepoint
New York
-$117K
3
Citadel Advisors
Citadel Advisors
Florida
-$108K
4
Sequoia Financial Advisors
Sequoia Financial Advisors
Ohio
-$64.1K
5
Simplex Trading
Simplex Trading
Illinois
-$48.4K

CLRB Hedge Fund Activity: Q2 2025 in Review

19 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2025, worth a combined $734K — down 55% from $1.63M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of CLRB and 6 opened new positions — a net loss of 13 holders — while 9 trimmed existing stakes and 2 added.

The largest buyer was HRT Financial, adding an estimated $96.6K. The largest seller was UBS Group, cutting an estimated $237K.

  • 19 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2025, down from 32 in Q1 2025.
  • Funds reported $734K of Cellectar Biosciences stock for Q2 2025, down 55% quarter-over-quarter.
  • 6 funds opened new Cellectar Biosciences positions in Q2 2025 and 19 closed out, a net change of -13 holders.
  • The largest Cellectar Biosciences buyer in Q2 2025 was HRT Financial, an estimated $96.6K added.
  • The largest Cellectar Biosciences seller in Q2 2025 was UBS Group, an estimated $237K sold.

Based on aggregated 13F filings for Q2 2025.